Published in J Hypertens on December 01, 2002
Systematic drug repositioning based on clinical side-effects. PLoS One (2011) 1.56
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int (2004) 6.32
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med (2003) 5.47
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet (2009) 4.73
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81
Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol (2004) 3.63
Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation (2002) 3.27
Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med (2003) 2.80
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol (2006) 2.51
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation (2004) 2.30
Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol (2009) 2.24
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
LDL cholesterol in CKD--to treat or not to treat? Kidney Int (2013) 2.17
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J (2013) 2.12
Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. J Am Soc Nephrol (2002) 2.09
Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol (2008) 2.09
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol (2008) 1.93
Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant (2008) 1.89
First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol (2008) 1.86
A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis (2003) 1.82
Evaluation of measures of urinary albumin excretion. Am J Epidemiol (2006) 1.78
Does the European clinical trials directive really improve clinical trial approval time? Br J Clin Pharmacol (2008) 1.77
Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol (2003) 1.75
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst (2012) 1.68
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int (2012) 1.65
The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl (2005) 1.61
AMP-activated protein kinase as a target for preconditioning in transplantation medicine. Transplantation (2010) 1.59
Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int (2002) 1.53
The kidney in type 2 diabetes therapy. Rev Diabet Stud (2011) 1.50
Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors. Nephrol Dial Transplant (2010) 1.48
The role of angiotensin(1-7) in renal vasculature of the rat. J Hypertens (2006) 1.47
Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotally nephrectomized rats. J Hypertens (2006) 1.46
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J (2011) 1.43
Adjunct nitrous oxide normalizes vascular reactivity changes after hemorrhagic shock in mice under isoflurane anesthesia. Anesthesiology (2009) 1.40
CKD treatment: time to alter the focus to albuminuria? Adv Chronic Kidney Dis (2011) 1.39
Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. Nephrol Dial Transplant (2012) 1.39
Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol (2005) 1.34
Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol (2010) 1.32
Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol (2006) 1.31
Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol (2006) 1.25
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J (2005) 1.25
Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol (2006) 1.23
Induction of heat shock response protects the heart against atrial fibrillation. Circ Res (2006) 1.20
Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration. Kidney Int Suppl (2005) 1.16
Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol (2004) 1.15
Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens (2006) 1.15
Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl (2011) 1.15
Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant (2006) 1.14
Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. Am J Kidney Dis (2012) 1.13
Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res (2002) 1.12
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol (2008) 1.12
Review: relation between quality-of-care indicators for diabetes and patient outcomes: a systematic literature review. Med Care Res Rev (2011) 1.10
Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol (2008) 1.10
Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis (2011) 1.09
N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J (2009) 1.08
Apparent loss of urinary albumin during long-term frozen storage: HPLC vs immunonephelometry. Clin Chem (2007) 1.08
The geographical distribution of leadership in globalized clinical trials. PLoS One (2012) 1.08
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant (2013) 1.07
Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care (2005) 1.07
The association between atherosclerotic risk factors and renal function in the general population. Kidney Int (2005) 1.07
Low body temperature governs the decline of circulating lymphocytes during hibernation through sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2011) 1.06
Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res (2002) 1.05
Optimization of ultrasound and microbubbles targeted gene delivery to cultured primary endothelial cells. J Drug Target (2007) 1.04
C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. Atherosclerosis (2004) 1.04
Collaboration on progress testing in medical schools in the Netherlands. Med Teach (2010) 1.03
Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples. Clin Chem (2005) 1.03
Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol (2004) 1.03
Specific drug delivery to the kidney. Cardiovasc Drugs Ther (2002) 1.02
What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol (2007) 1.01
Composite renal endpoints: was ACCOMPLISH accomplished? Lancet (2010) 1.01
Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus--a cohort study. PLoS One (2012) 1.01
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol (2014) 1.01
Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. Am Heart J (2004) 1.00
Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. J Nephrol (2006) 1.00
HSPB1, HSPB6, HSPB7 and HSPB8 protect against RhoA GTPase-induced remodeling in tachypaced atrial myocytes. PLoS One (2011) 1.00
Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? Nephrol Dial Transplant (2003) 0.98
A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness. PLoS One (2011) 0.98
Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol (2008) 0.97
Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation. Cardiovasc Res (2004) 0.97